Forte Biosciences Inc (FBRX) USD0.001
Sell:$6.50Buy:$7.70
$0.41
(6.16%)
- This stock can be held in a
Stocks and Shares ISA$0.41
(6.16%)$0.41
(6.16%)Company Information
About this company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Key people
Key facts
- EPICFBRX
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS34962G2084
- Market cap$44.14m
- Employees14
- Shares in issue6.58m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.